Skip to content
AnalystLens

AbbVie Inc. 8-K Report, Financial Results (Jul 31, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 31, 2026
Period End
July 31, 2026
Security
ABBV
In the record · 2016–202610-K1110-Q328-K163

ABBV filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 163 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’16Nov ’16
  2. Impairment8-K · Jan ’19Jan ’19
  3. Leadership change8-K · Jan ’21Jan ’21
  4. Leadership change8-K · May ’25May ’25

01—Abstract

Summary

Summary of the 8-K filed July 31, 2026. Cited figures are marked; the original filing is the authoritative source.

AbbVie reported second-quarter 2026 results that beat expectations on revenue and profitability, led by its immunology franchise.

Net revenues rose 10.2% on a reported basis (9.5% operational) to $16.990 billiona. Immunology grew 15.1% to $8.786 billion, driven by Skyrizi ($5.505 billion, up 24.4%) and Rinvoq ($2.525 billion, up 24.5%), which offset a 35.9% decline in Humira to $756 million. Neuroscience rose 20.3% to $3.228 billion, with Vraylar, Botox Therapeutic, Ubrelvy/Qulipta and Vyalev all growing.

Oncology declined 1.5% to $1.650 billionb as Imbruvica fell 29.4%, partly offset by Venclexta and Elahere growth. Aesthetics was roughly flat at $1.282 billion. GAAP diluted EPS was $2.03, up 290.4% from $0.52, while adjusted diluted EPS was $3.65, up 22.9%.

Both figures include a $0.17c per-share charge for acquired IPR&D and milestones. The main strategic development is AbbVie's definitive agreement to acquire Apogee Therapeutics, valued at approximately $10.9 billion in total equity. The deal adds zumilokibart (APG777), a late-stage IL-13 antibody for atopic dermatitis, and APG273, a long-acting IL-13/TSLP combination for asthma, and is expected to close in the third quarter of 2026.

AbbVie updated its 2026 adjusted diluted EPS guidance to $13.87 to $14.07d, from $13.91 to $14.11. The midpoint falls by $0.04 because the Apogee deal is expected to be $0.14 dilutive, partly offset by $0.10 of operational overperformance. The guidance also reflects $0.58 per share of year-to-date acquired IPR&D and milestone expense and excludes any such charges after the second quarter.

For investors, the quarter shows strong underlying growth in the Skyrizi and Rinvoq franchises and continued execution in neuroscience, while the Humira and Imbruvica declines and sizable acquisition-related items weigh on the outlook. Key points to monitor are the Apogee closing timeline and integration, Humira and Imbruvica erosion, and the sustainability of the immunology growth rate. The filing does not disclose the deal price per share, financing structure, or any updated pipeline timelines beyond the press release highlights.

02—Key points

Key Highlights

  1. Revenue of $16.990 billion grew 10.2% reported (9.5% operational), with immunology up 15.1% to $8.786 billion, led by Skyrizi ($5.505 billion, +24.4%) and Rinvoq ($2.525 billion, +24.5%).
  2. GAAP diluted EPS was $2.03, up 290.4% year over year, and adjusted diluted EPS was $3.65, up 22.9%. Both include a $0.17 per-share unfavorable impact from acquired IPR&D and milestones.
  3. Adjusted operating margin was 48.3% and GAAP operating margin was 37.9%. Operating earnings rose to $6.432 billion from $4.894 billion.
  4. Neuroscience grew 20.3% to $3.228 billion, with Vraylar at $1.071 billion, Botox Therapeutic at $1.042 billion, Ubrelvy and Qulipta combined at $742 million, and Vyalev at $256 million.
  5. Humira fell 35.9% to $756 million and Imbruvica fell 29.4% to $532 million, reflecting ongoing biosimilar and generic erosion in legacy franchises.
  6. AbbVie agreed to acquire Apogee Therapeutics at an approximate total equity value of $10.9 billion, adding IL-13 and IL-13/TSLP assets for atopic dermatitis and asthma, with closing expected in Q3 2026.
  7. 2026 adjusted diluted EPS guidance was narrowed to $13.87 to $14.07 from $13.91 to $14.11, a $0.04 midpoint reduction driven by the $0.14 Apogee dilution partly offset by $0.10 of overperformance.

03—Questions

Frequently Asked Questions

  1. Why did GAAP EPS rise so much more than adjusted EPS?

    The prior-year quarter carried much larger non-cash charges. Q2 2025 GAAP EPS of $0.52 included a $2.795 billion pre-tax change in the fair value of contingent consideration and $1.864 billion of intangible amortization. In Q2 2026, the contingent consideration charge was $1.518 billion and amortization was $1.689 billion. Because adjusted EPS excludes these items, the gap between GAAP and adjusted growth narrowed sharply.

  2. How much is the Apogee acquisition expected to affect 2026 earnings?

    Management expects the transaction to be $0.14 per share dilutive to 2026 adjusted diluted EPS, assuming a third-quarter 2026 close. Approximately $0.10 of operational overperformance offsets part of that impact, leaving a net $0.04 reduction at the guidance midpoint.

  3. What does the guidance exclude, and why does it matter?

    The $13.87 to $14.07 range includes $0.58 per share of acquired IPR&D and milestone expense incurred through June 30, 2026. It excludes any further IPR&D or milestone charges, because management says these cannot be reliably forecast. Future charges could reduce reported adjusted EPS relative to the range.

  4. Is the growth in immunology sustainable given Humira's decline?

    Skyrizi and Rinvoq together generated about $8.03 billion in the quarter, or roughly 47% of total revenue, and grew around 24% each. That growth more than offset Humira's $756 million decline in revenue. The filing does not provide guidance on long-term franchise trajectories, so investors should weigh the strength of current growth against competitive dynamics and the continued erosion of legacy products.

04—Continue

← View all 8-K filings